Vaxcyte (NASDAQ:PCVX) Given Buy Rating at Guggenheim

Guggenheim restated their buy rating on shares of Vaxcyte (NASDAQ:PCVX) in a report published on Wednesday morning,Benzinga reports. Guggenheim currently has a $160.00 price objective on the stock.

PCVX has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $78.65 on Wednesday. The company has a 50 day simple moving average of $85.10 and a 200-day simple moving average of $94.88. The company has a market capitalization of $9.80 billion, a P/E ratio of -17.10 and a beta of 0.98. Vaxcyte has a 1 year low of $58.10 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte will post -4.21 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $19,024,730.55. The trade was a 3.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 76,616 shares of company stock valued at $6,766,481 in the last 90 days. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Institutional investors have recently modified their holdings of the company. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the 4th quarter worth $28,000. Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new stake in Vaxcyte in the fourth quarter valued at $41,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after acquiring an additional 775 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.